Auxiliary screening and scientific research services for major diseases of the urinary system
Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Detection indicators: sarcosine, alanine, glycine, glutamic acid
Sample type: urine
Specification: 96 servings/box
Clinical significance
The development of some tumor screenings has resulted in a significant decrease in the incidence and mortality of advanced tumors in the screening population. Based on the late stage of newly diagnosed prostate cancer in my country, early prostate cancer has hidden characteristics, and the existence of effective treatment measures for early prostate cancer, as well as the support of foreign research and literature reports, it is of great significance to carry out prostate cancer screening in my country.
In 2009, an article published in Nature stated that sarcosine entered people's attention as a marker for prostate cancer. The diagnosis of prostate cancer based on the sarcosine pathway has the advantages of non-invasive, fast, and accurate quantification, and complements the advantages of PSA. It can play the greatest predictive role in the screening of prostate cancer, eliminate interference, make accurate diagnosis, and reduce the cost of biopsy to patients. The pain that comes.
Domestic clinical application research verification
Urinary sarcosine content is significantly increased in prostate cancer patients, and its degree of increase is significantly related to the pathological grade of prostate cancer. It is recommended as an ideal marker for early screening.
Featured application of Health Biotech: Early screening and evaluation of major diseases of the urinary system
metabolomics platform, using liquid chromatography tandem mass spectrometry (LC-MS/MS), on the basis of foreign research, a PCA (four amino acids target- Creatine, glycine, alanine, glutamic acid; two calculated values) can help distinguish prostate cancer, benign prostatic hyperplasia and prostatitis, and can also complement the advantages of PSA to assist PSA gray zone assessment of major prostate diseases .
Based on the metabolomics platform, using liquid chromatography tandem mass spectrometry (LC-MS/MS), based on foreign novel researches, successfully developed a prostate cancer early screening diagnostic product PCA (four amino acid targets-muscle Amino acid, glycine, alanine, glutamate; two calculated values), can distinguish prostate cancer, benign prostatic hyperplasia and prostatitis, can be used for early prostate cancer screening, can also complement the advantages of PSA, to assist PSA gray District diagnosis of prostate cancer.
